D
etermination of glycated hemoglobin (HbA1c) concentrations is recommended to diagnose and monitor the treatment of diabetes mellitus.
1,2 HbA1c is continuously generated over the life span of a red blood cell (RBC) via nonenzymatic glycation. Via this posttranslational process, (D-)glucose is covalently bound to a protein, in this case a minor hemoglobin. The rate of nonenzymatic glycation mainly depends on glucose concentration and RBC turnover. 3, 4 Consequently, several endogenous and exogenous factors can alter HbA1c test results and thereby mask the true glycemic state of a patient. The most relevant factors for reduced or elevated HbA1c concentrations are anemia, due to its effects on RBC life span, and transfusion of RBCs, respectively. 2, 5 High glucose concentrations are required in storage solutions of RBCs to provide energy for the metabolically active RBCs. To our knowledge, only one retrospective study has evaluated the effects of RBC transfusions on HbA1c concentrations in patients, 6 and no consensus has been reached about whether RBC transfusions elevate or reduce HbA1c concentrations. Moreover, reports on temporal evolution of HbA1c concentrations during storage of RBCs provide contradictory data. [6] [7] [8] [9] [10] This lack of data and evidence has prompted some authors to conclude that HbA1c values of patients having received transfusions must be considered uninterpretable. 5 The aim of this study was to assess HbA1c concentrations of RBCs during the maximum allowed storage period of 42 days. In this report, we present the results of a singlearm study comparing HbA1c concentrations between Day 1 and Day 42 of storage measured by using three different standardized validated devices.
MATERIALS AND METHODS
The study was approved by the Ethics Committee of the Medical University of Vienna (1043/2015) and registered at http://clinicaltrials.gov (NCT02639780). Sixteen healthy volunteers donated 1 RBC unit after providing written informed consent. Blood was leukofiltered (log 4 leukocyte reduction), processed according to standard protocols of transfusion services of the Austrian Red Cross (Vienna, Austria), and stored in a saline-adenine-glucose-mannitol solution under standard blood banking conditions at 4 C for 42 days. Samples were drawn aseptically from storage bags on Day 1 and Day 42, and HbA1c as well as glucose concentrations were measured. HbA1c was measured independently by three different standardized validated devices based on two biochemical methods. First (referred to as Method A1), HbA1c was assessed using a Bio-Rad D-100 (Bio-Rad Laboratories). This method is based on ion-exchange high-performance liquid chromatography (HPLC) and represents the standard method to determine HbA1c at our institution. Second (referred to as Method A2), HbA1c was measured using a Bio-Rad D-10 (Bio-Rad Laboratories), an alternative HPLCbased platform. Third (referred to as Method B), HbA1c was measured using a turbidimetric immunoassay on an Advia 1800 (Siemens Healthcare Diagnostics). All three methods were applied according to manufacturers' instructions.
Glucose concentrations in the storage solution of RBCs were measured with a Glucose HK Gen.3 kit on a Roche/ Hitachi cobas c System (Roche Diagnostics).
Statistical analysis was performed using GraphPad Prism v.7.02 (GraphPad Software, Inc.). Data distribution was analyzed visually (histogram) and by using the D'AgostinoPearson omnibus normality test. Changes of HbA1c and glucose values between Day 1 and Day 42 were analyzed using a paired t test. Differences of HbA1c concentrations at baseline between the different methods were assessed using a one-way analysis of variance and the Tukey multiple comparison test. Correlations of HbA1c concentrations between methods were calculated according to Pearson. Normally distributed data are reported as means AE standard deviation, and all other data as median and range. Differences are reported as mean differences and 95% confidence intervals (CIs). All HbA1c concentration changes are reported as absolute percentage points unless otherwise indicated.
RESULTS
In total, blood was drawn from 16 donors, eight men and eight women, with an average age of 47 years (Table 1 Fig. 1C ). All HbA1c values were below the generally accepted limits for nondiabetic patients (<6.5%). 11 Only the results between Method A2 and B were statistically different; however, they were of borderline or no clinical significance (mean difference 0.4%, 95% CI, 0.03-0.7, p = 0.028). Correlations of HbA1c concentrations between methods are depicted in Fig. S1 (available as supporting Glucose concentrations in the storage solution of RBCs were supraphysiologic on Day 1 (495 AE 27 mg/dL). To confirm that the stored RBCs were metabolically active, glucose concentrations were measured again on Day 42. Glucose concentrations decreased by more than 50% to 225 AE 55 mg/dL (p < 0.0001).
DISCUSSION
In this study, we demonstrated a significant but minor increase of HbA1c concentrations from Day 1 through Day 42 in RBCs stored under standard blood banking conditions.
Our data are in agreement with an early study by Zeller and colleagues, in which blood was drawn from 10 fasted volunteers and subsequently stored for 35 days. 10 The authors reported HbA1c concentrations, measured by HPLC, of 6.0% on Day 1 and 6.6% on Day 35, although the difference was not significant. Apart from the fact that baseline HbA1c concentrations suggest impaired glucose metabolism in at least some subjects of the study population, the reported increase of HbA1c is comparable with our observed absolute increase of 0.3%. In addition, Spencer and colleagues reported HbA1c concentrations of 5.4% and 5.7% in two unused RBC units on Day 42 of storage. 6 These results parallel our data, where the mean HbA1c across all methods was 5.6 AE 0.3% on Day 42 of storage.
In contrast, Szelenyi and colleagues, who drew blood from five healthy donors and subsequently stored the whole blood for 3 weeks in acid citrate-phosphate preservatives at 4 C, reported an increase of the HbA1c of 2.0 AE 0.5%, based on a colorimetric method. 8 Although the mean baseline HbA1c (5.7%) is similar to our results, the authors reported a significantly larger increase during storage. These diverging results might be influenced by the method used to determine HbA1c concentrations, storage conditions, and because whole blood is an entirely different product compared with the leukofiltered RBCs used in our study. Interestingly, D'Alessandro and colleagues, who stored leukodepleted RBC units collected from 10 healthy volunteers for 42 days, reported a statistically and potentially clinically significant change of the HbA1c from 4.1 AE 0.3% to 10.9 AE 0.3%. 7 This drastic increase might be explained by the method used to determine HbA1c concentrations because quantification of HbA1c by means of MALDI-TOF mass spectrometry-based analysis is not a standard method of measuring HbA1c. Furthermore, differences in leukoreduction, manufacturing, and storage conditions, as well as varying anticoagulants or additive solutions, might contribute to these differences. Clinically, the question of whether HbA1c concentrations are altered in (diabetic) patients receiving RBC transfusions remains unclear because no prospective studies have investigated this issue. The only study to date by Spencer and colleagues is a retrospective analysis of patients transfused with RBCs. 6 Among the 45 patients analyzed, ratio of the transfused blood to the patient's blood of 1:10 in an adult man. Taken together, our data suggest that HbA1c concentrations are significantly higher in RBC units after 42 days of storage, although this increase might not be clinically relevant. Carefully extrapolating these data infers that HbA1c concentrations most likely decrease when diabetic patients with elevated HbA1c values receive RBC transfusions. The data generated in this study might facilitate the interpretation of HbA1c concentrations in transfused diabetic patients. 
